Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05001373 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)
A Phase 1 study of HIV, sponsored by International AIDS Vaccine Initiative.
- Active
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 4
- Study locations
NCT05001373 is a Phase 1 study of HIV that is active but no longer recruiting, run by International AIDS Vaccine Initiative. The registered enrollment target is 56 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05001373, a Phase 1 study of HIV, is active but no longer recruiting, sponsored by International AIDS Vaccine Initiative.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General Health
Conditions Studied
Interventions
- BIOLOGICAL Core-g28v2 60mer mRNA Vaccine
- BIOLOGICAL eOD-GT8 60mer mRNA Vaccine
Study Locations (4)
District of Columbia
- George Washington University - Washington D.C.
Georgia
- Emory University - Atlanta
Texas
- UT Health San Antonio - San Antonio
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-11-12 |
| Est. Completion | 2024-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05001373
The ClinicalTrials.gov registry entry for NCT05001373 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (87% lower). The listed sponsor is International AIDS Vaccine Initiative, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Core-g28v2 60mer mRNA Vaccine is the first listed.
NCT05001373 reports 4 study locations spanning 4 distinct geographic areas - top geographies include District of Columbia, Georgia, Texas.
Frequently Asked Questions
What is clinical trial NCT05001373 about?
NCT05001373 is a clinical study titled "A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)". A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General Health
What is the current status of trial NCT05001373?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2021-11-12. Estimated completion is 2024-07-01.
What conditions does trial NCT05001373 study?
This clinical trial studies the following conditions: HIV.
What interventions are being tested in trial NCT05001373?
The interventions under investigation include: Core-g28v2 60mer mRNA Vaccine (BIOLOGICAL), eOD-GT8 60mer mRNA Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05001373?
This trial is sponsored by International AIDS Vaccine Initiative, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05001373 being conducted?
This trial has 4 study locations across District of Columbia, Georgia, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
RECRUITING · Phase 1
-
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
RECRUITING · Phase 1
-
Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV
RECRUITING · Phase 1
-
HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)
RECRUITING · Phase 1
-
A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV
ACTIVE NOT RECRUITING · Phase 1
-
Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.